European Union Awarded €2.9M Grant to Breast and Colon Cancer Biomarker Research Project
Complete the form below to unlock access to ALL audio articles.
IPSOGEN announced that COBRED project coordinated by BioSystems International (Paris) has been awarded a €2.9 M grant as part of the 6th Framework Programme.
COBRED project aims at discovering breast cancer (BC) and colon cancer (CRC) biomarkers for patient follow-up (monitoring markers) by exploiting the capacity of 3 high-throughput technologies in an integrated systems biology approach.
In addition to Ipsogen, the consortium comprises 2 other biotechnology firms (BioSystems International, coordinator – Paris, France; Biocrates – Innsbrück, Austria), 2 large cancer centres (Institut Curie - Paris, France; Institut Gustave Roussy, - Villejuif, France) and 3 academic partners (University of Debrecen, Hungary; University of Innsbrück, Austria; University of Tartu, Estonia); the consultancy firm ARTTIC (Paris, France) will support the consortium for project management.
After 3 years, COBRED will deliver a set of biomarker candidates verified in preclinical studies, ready for large scale clinical validation and further development for commercialisation by the respective biotechnology firms.
Furthermore COBRED will have demonstrated the potential to explore consolidated data resulting from different high-throughput technologies and clinical profiles with advanced data mining technologies for enhanced biomarker discovery. Although within the project scope COBRED focuses on biomarkers for follow-up diagnostics, it has the potential to evolve to an early cancer detection & screening tool.
“Ipsogen has already been successful in leveraging European academic R&D and clinical networks in blood cancers (e.g. Europe Against Cancer and European LeukemiaNet) for discovery and validation of follow-up biomarkers. With the COBRED project we are now building a powerful research platform, aggregating major technologies and clinical expertise with the exciting goal of defining new tools for the monitoring of Breast and Colon cancer treatments” said Vincent Fert, Ipsogen’s Chief Executive Officer.
This work is supported by funding under the Sixth Research Framework Programme of the European Union, Project COBRED.
